China Pharma Inc.

AMEX: CPHI · Real-Time Price · USD
1.46
0.00 (0.00%)
At close: Aug 15, 2025, 9:59 AM

China Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1,136.3B 1.13M 1.1M 924.94K 1.37M 2.15M 1.8M 1.1M 1.96M 2.92M 1.97M 1.61M 1.6M 2.89M 1.98M 2.42M 2.36M
Cost of Revenue
1,272.3B 1.29M 1.62M 2.05M 1.66M 2.29M 2.04M 1.24M 1.78M 2.88M 2.1M 1.84M 1.77M 2.59M 2.28M 2.34M 2.09M
Gross Profit
-136.06B -160.59K -519.65K -1.12M -290.02K -141.42K -233.19K -146.66K 177.92K 42.68K -137.76K -229.38K -169.46K 301.94K -296.4K 71K 272.73K
Operating Income
-758.62B -1.2M -1.09M -1.39M -916.05K -1.18M -713.54K -456.31K 953.2K -1.18M -688.65K -779.59K -911.72K 772.74K -762.4K -752.95K -696.47K
Interest Income
1.07B 1.33K 1.46K 1.53K 2.31K 2.53K 2.18K 942.00 948.00 1K 1.86K 1.24K 6.66K 1.41K 638.00 579.00 406.00
Pretax Income
-785.57B -1.22M -1.12M -1.44M -955.89K -1.23M -777.6K -593.03K -475.98K -1.26M -790.77K -888.39K -1.03M -980.72K -826.67K -824.76K -767.33K
Net Income
-785.57B -1.22M -1.12M -1.44M -955.89K -1.23M -777.6K -593.03K -1.99M -1.35M -790.77K -2.47M -2.69M -3.07M -826.67K -824.76K -767.33K
Selling & General & Admin
594.29B 1.03M 479.65K 203.32K 596.64K 895.52K 452.79K 281.85K 562.43K 1.18M 535.99K 535.15K 688.21K 1.15M 436.26K 770.49K 787.33K
Research & Development
29.59B 547.00 87.61K 164.33K 31.45K 147.55K 45.77K 23.75K 23.01K 28K 88.75K 15.06K 54.05K 54.05K 21.37K 53.46K 190.09K
Other Expenses
n/a 948.00 n/a -96.45K -2.07K n/a n/a n/a 10.04K 10.14K n/a 4.36K 5.52K n/a 8.37B n/a n/a
Operating Expenses
623.88B 895.12K 565.61K 271.21K 626.03K 1.04M 498.56K 305.6K 585.44K 1.22M 624.73K 554.57K 747.78K -950.63K -466.01K -823.95K -969.2K
Interest Expense
-28.03B 29.73K 34.11K 48.14K 42.16K 50.25K 66.24K 137.66K 79.44K 96.17K 103.98K 110.04K 124.43K 333.44K 64.9K 72.39K 71.27K
Selling & Marketing Expenses
87.11B 174.58K 134.6K 111.45K 108.19K 259.55K 206.52K 169.82K 144.43K 364.4K 259.38K 266.45K 179.56K 536.9K 134.29K 445.48K 378.33K
Cost & Expenses
1,896.2B 2.33M 2.19M 2.32M 2.29M 3.33M 2.54M 1.55M 1.21M 1.67M 2.73M 1.29M 1.03M 1.64M 1.81M 1.52M 1.12M
Income Tax Expense
n/a n/a n/a n/a n/a 3.00 n/a n/a 1.52M 83.72K n/a 1.58M 1.66M 2.09M n/a n/a n/a
Shares Outstanding (Basic)
32.62M 17.46M 17.31M 16.12M 13.13M 10.63M 10.57M 9.92M 8.08M 6.44M 4.61M 4.85M 4.74M 4.78M 4.61M 4.61M 4.61M
Shares Outstanding (Diluted)
32.62M 17.46M 17.31M 16.12M 13.13M 10.63M 10.57M 9.92M 8.08M 6.44M 4.61M 4.94M 4.74M 4.78M 4.61M 4.61M 4.61M
EPS (Basic)
-24.08K -0.07 -0.06 -0.09 -0.07 -0.12 -0.07 -0.06 -0.25 -0.21 -0.79 -0.51 -0.57 -0.64 -0.18 -0.18 -0.17
EPS (Diluted)
-24.08K -0.07 -0.06 -0.09 -0.07 -0.12 -0.07 -0.06 -0.25 -0.21 -0.79 -0.5 -0.57 -0.64 -0.18 -0.18 -0.17
EBITDA
-758.62B -746.63K -386.85K -648.35K -179.94K -486.12K -28.27K 240.77K 283.35K -528.58K -22.46K -94.74K -191.51K 63.44K 214.69K -51.91K 4.13K
EBIT
n/a -1.19M -1.08M -1.39M -913.74K -1.18M -711.36K -455.37K -396.53K -1.17M -686.8K -778.35K -905.06K -647.28K -761.77K -752.37K -696.06K
Depreciation & Amortization
n/a 448.07K 696.94K 741.64K 733.8K 695.84K 683.09K 696.14K 679.88K 639.42K 664.34K 683.61K 713.56K 710.72K 976.46K 700.46K 700.19K